Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
7 "Biomarker"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
IBD
Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Sanshiro Kobayashi, Mamiko Aoi, Takashi Tomiyama, Tomomitsu Tahara, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma
Intest Res 2025;23(2):170-181.   Published online August 19, 2024
DOI: https://doi.org/10.5217/ir.2024.00042
AbstractAbstract PDFPubReaderePub
Background/Aims
Serum leucine-rich alpha-2 glycoprotein (LRG) is a potential biomarker of Crohn’s disease (CD). This study aimed to evaluate the usefulness of LRG in predicting clinical relapse in patients in remission with CD.
Methods
This retrospective observational study assessed the relationships among patient-reported outcome (PRO2), LRG, and other blood markers. The influence of LRG on clinical relapse was assessed in patients in remission with CD.
Results
Data of 94 patients tested for LRG between January 2021 and May 2023 were collected. LRG level did not correlate with PRO2 score (ρ = 0.06); however, it strongly correlated with C-reactive protein (CRP) level (r=0.79) and serum albumin level (r=–0.70). Among 69 patients in clinical remission, relapse occurred in 22 patients (31.9%). In the context of predicting relapse, LRG showed the highest area under the curve, followed by CRP level, platelet count, and albumin level. Multivariate analysis revealed that only LRG (P= 0.02) was an independent factor for predicting clinical remission. The cumulative non-relapse rate was significantly higher in patients with LRG < 13.8 μg/mL than in patients in remission with LRG ≥ 13.8 μg/mL and normal CRP level (P= 0.002) or normal albumin level (P= 0.001). Cumulative non-relapse rate was also higher in patients with LRG < 13.8 μg/mL compared to those with LRG ≥ 13.8 μg/mL in patients with L3 or B2+B3 of Montreal calcification.
Conclusions
LRG is useful in predicting clinical relapse in patients with CD during biological remission. LRG is a useful biomarker for predicting prognosis, even in patients with intestinal stenosis, or previous/present fistulas.
  • 2,136 View
  • 177 Download
Close layer
IBD
Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
Ryo Karashima, Shintaro Sagami, Yoko Yamana, Masa Maeda, Aya Hojo, Yusuke Miyatani, Masaru Nakano, Takahisa Matsuda, Toshifumi Hibi, Taku Kobayashi
Intest Res 2024;22(4):473-483.   Published online June 5, 2024
DOI: https://doi.org/10.5217/ir.2023.00135
AbstractAbstract PDFPubReaderePub
Background/Aims
Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated.
Methods
Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) were prospectively enrolled. Associations of LRG, C-reactive protein (CRP) and fecal calprotectin (FC) at baseline, week 1, and week 8 with clinical remission at week 8 and subsequent endoscopic improvement within 1 year (Mayo endoscopic subscore of 0 or 1) were assessed.
Results
A total of 143 patients with UC were included. LRG and CRP at week 1 were significantly lower in the clinical remission group than in the non-remission group (LRG, 20.6 μg/mL vs. 28.4 μg/mL, P< 0.001; CRP, 0.9 mg/dL vs. 2.3 mg/dL, P< 0.001) while FC demonstrated the difference between groups only at week 8. The area under the curves of week 1 LRG, CRP, and FC for week 8 clinical remission using the receiver operating characteristic curves analysis were 0.68, 0.71, and 0.57, respectively. Furthermore, LRG and CRP predicted subsequent endoscopic improvement as early as week 1, while FC was predictive only at week 8.
Conclusions
LRG can be an early-phase biomarker predicting subsequent clinical and endoscopic response to induction therapy.

Citations

Citations to this article as recorded by  
  • The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn’s disease
    M. H. Rasmussen, J. B. Brodersen, C. L. Brasen, J. S. Madsen, T. Knudsen, J. Kjeldsen, M. D. Jensen
    Scandinavian Journal of Gastroenterology.2025; 60(3): 235.     CrossRef
  • Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis
    Yuki Aoyama, Sakiko Hiraoka, Eriko Yasutomi, Toshihiro Inokuchi, Takehiro Tanaka, Kensuke Takei, Shoko Igawa, Keiko Takeuchi, Masahiro Takahara, Junki Toyosawa, Yasushi Yamasaki, Hideaki Kinugasa, Jun Kato, Hiroyuki Okada, Motoyuki Otsuka
    Scientific Reports.2025;[Epub]     CrossRef
  • Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
    Yasuhiro Takagi, Toshiyuki Sato, Takanori Nishiguchi, Akira Nogami, Masataka Igeta, Soichi Yagi, Maiko Ikenouchi, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Toshihiko Tomita, Hirokazu Fukui, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki
    Alimentary Pharmacology & Therapeutics.2025; 61(12): 1923.     CrossRef
  • Leucine-Rich Alpha-2 Glycoprotein 1 as a Biomarker for Evaluation of Inflammatory Bowel Disease Activity in Children
    Betül Aksoy, Yeliz Çağan Appak, Murat Akşit, Serenay Çetinoğlu, Sinem Kahveci, Şenay Onbaşı Karabağ, Selen Güler, İlksen Demir, İnanç Karakoyun, Maşallah Baran
    Journal of Clinical Medicine.2025; 14(8): 2803.     CrossRef
  • Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
    Shinichiro Shinzaki, Yasuhiro Takagi, Toshiyuki Sato
    Alimentary Pharmacology & Therapeutics.2025; 61(12): 1967.     CrossRef
  • 2,937 View
  • 217 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Review
Colorectal neoplasia
Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration
Chang Kyo Oh, Young-Seok Cho
Intest Res 2024;22(2):131-151.   Published online February 1, 2024
DOI: https://doi.org/10.5217/ir.2023.00115
AbstractAbstract PDFPubReaderePub
Colorectal cancer (CRC) ranks third in cancer incidence and stands as the second leading cause of cancer-related deaths globally. CRC tumorigenesis results from a cumulative set of genetic and epigenetic alterations, disrupting cancer-regulatory processes like cell proliferation, metabolism, angiogenesis, cell death, invasion, and metastasis. Key epigenetic modifications observed in cancers encompass abnormal DNA methylation, atypical histone modifications, and irregularities in noncoding RNAs, such as microRNAs and long noncoding RNAs. The advancement in genomic technologies has positioned these genetic and epigenetic shifts as potential clinical biomarkers for CRC patients. This review concisely covers the fundamental principles of CRC-associated epigenetic changes, and examines in detail their emerging role as biomarkers for early detection, prognosis, and treatment response prediction.

Citations

Citations to this article as recorded by  
  • Influence of Lifestyles on Polyp Burden and Cancer Development in Hereditary Colorectal Cancer Syndromes
    Hye Kyung Hyun, Ji Soo Park, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Journal of Gastroenterology and Hepatology.2025; 40(2): 433.     CrossRef
  • The role of suppressor of cytokine signaling 3 in inflammatory bowel disease and its associated colorectal cancer
    Pengfei Zhang, Bing Pei, Chengxue Yi, Francis Atim Akanyibah, Fei Mao
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(2): 167578.     CrossRef
  • Chronic Kidney Disease Increases Risk of Delayed Post‐Polypectomy Bleeding: A Large‐Scale Propensity Score‐Matched Analysis
    Hye Kyung Hyun, Nak‐Hoon Son, So Hyeon Gwon, Hyun Chul Lim, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Tae‐Hyun Yoo, Shin‐Wook Kang, Hae‐Ryong Yun, Cheal Wung Huh
    United European Gastroenterology Journal.2025;[Epub]     CrossRef
  • An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update
    Susmita Roy, Dikshita Deka, Suresh Babu Kondaveeti, Pavithra Ayyadurai, Sravani Siripragada, Neha Philip, Surajit Pathak, Asim K. Duttaroy, Antara Banerjee
    Epigenetics.2025;[Epub]     CrossRef
  • Minimum Platelet Count Threshold for Safe Colonoscopic Polypectomy: A Large-Scale Propensity Scored-Matched Analysis
    Hye Kyung Hyun, Nak-Hoon Son, Cheal Wung Huh, Hyun Chul Lim, So Hyeon Gwon, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    American Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Anthocyanins: From Natural Colorants to Potent Anticancer Agents
    Muhammad Maaz, Muhammad Tauseef Sultan, Ahmad Mujtaba Noman, Shehnshah Zafar, Naima Tariq, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Tadesse Fenta Yehuala, Ehab M. Mostafa, Samy Selim, Soad K. Al Jaouni, Suliman A. Alsagaby, Waleed Al Abdulmonem
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • Hsa-miR-21-5p and Hsa-miR-145-5p Expression: From Normal Tissue to Malignant Changes—Context-Dependent Correlation with Estrogen- and Hypoxia–Vascularization-Related Pathways Genes: A Pilot Study
    Mateusz Górecki, Aleksandra Żbikowska, Małgorzata Tokłowicz, Stefan Sajdak, Monika Englert-Golon, Mirosław Andrusiewicz
    International Journal of Molecular Sciences.2025; 26(9): 4461.     CrossRef
  • Epigenetically Regulating Non-coding RNAs in Colorectal Cancer: Promises and Potentials
    Zahra Taheri, Majid Zaki-Dizaji
    Middle East Journal of Digestive Diseases.2025; 17(1): 40.     CrossRef
  • miR-3065-5p and miR-26a-5p as Clinical Biomarkers in Colorectal Cancer: A Translational Study
    Berenice Carbajal-López, Antonio Daniel Martínez-Gutierrez, Eduardo O. Madrigal-Santillán, Germán Calderillo-Ruiz, José Antonio Morales-González, Jossimar Coronel-Hernández, Joey Lockhart, Oliver Millan-Catalan, Monica G. Mendoza-Rodriguez, Leonardo S. Li
    Cancers.2024; 16(21): 3649.     CrossRef
  • 5,799 View
  • 226 Download
  • 7 Web of Science
  • 9 Crossref
Close layer
Original Articles
IBD
Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
Intest Res 2024;22(1):65-74.   Published online November 9, 2023
DOI: https://doi.org/10.5217/ir.2023.00092
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients including the small bowel, and whether their combined use can improve accuracy.
Methods
One hundred and four consecutive patients with ileal and ileocolonic type CD who underwent balloon-assisted enteroscopy (BAE) from October 2021 to August 2022 were enrolled, with clinical and laboratory data prospectively collected and analyzed.
Results
Hemoglobin, platelet count, C-reactive protein, leucine-rich alpha-2 glycoprotein (LRG), fecal calprotectin, and fecal hemoglobin all showed significant difference in those with ulcers found on BAE. LRG and fecal calprotectin showed the highest areas under the curve (0.841 and 0.853) for detecting ulcers. LRG showed a sensitivity of 78% and specificity of 80% at a cutoff value of 13 μg/mL, whereas fecal calprotectin showed a sensitivity of 91% and specificity of 67% at a cutoff value of 151 μg/g. Dual positivity for LRG and fecal calprotectin, as well as LRG and fecal hemoglobin, both predicted ulcers with an improved specificity of 92% and 100%. A positive LRG or fecal calprotectin/hemoglobin showed an improved sensitivity of 96% and 91%. Positivity for LRG and either of the fecal biomarkers was associated with increased risk of hospitalization, surgery, and relapse.
Conclusions
The biomarkers LRG, fecal calprotectin, and fecal hemoglobin can serve as noninvasive and accurate tools for assessing activity in CD patients confirmed by BAE, especially when used in combination.

Citations

Citations to this article as recorded by  
  • Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn’s disease: a single-centre, cross-sectional study
    Yoshiaki Takada, Hiroki Kiyohara, Yohei Mikami, Masataka Taguri, Ryoya Sakakibara, Yasuhiro Aoki, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Motohiko Kato, Yasushi
    Annals of Medicine.2025;[Epub]     CrossRef
  • Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
    Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi
    World Journal of Gastrointestinal Endoscopy.2025;[Epub]     CrossRef
  • The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis
    Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel
    Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui
    Journal of Gastroenterology.2025; 60(5): 573.     CrossRef
  • Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
    Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Sanshiro Kobayashi, Mamiko Aoi, Takashi Tomiyama, Tomomitsu Tahara, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma
    Intestinal Research.2025; 23(2): 170.     CrossRef
  • Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
    Kensuke Takei, Toshihiro Inokuchi, Sakiko Hiraoka, Mikako Ishiguro, Junki Toyosawa, Yuki Aoyama, Shoko Igawa, Keiko Takeuchi, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Seiji Kawano, Toshiharu Mitsuhashi, Motoyuki Otsuka
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study
    Natsuki Ishida, Satoshi Tamura, Tomohiro Takebe, Kenichi Takahashi, Yusuke Asai, Tomoharu Matsuura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Takanori Yamada, Satoshi Osawa, Ken Sugimoto
    Inflammatory Bowel Diseases.2025;[Epub]     CrossRef
  • Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
    Jihye Park
    Intestinal Research.2024; 22(1): 1.     CrossRef
  • Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn’s disease small bowel lesion in capsule endoscopy
    Teppei Omori, Miki Koroku, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
    Intestinal Research.2024; 22(4): 464.     CrossRef
  • Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
    Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kiz
    Scientific Reports.2024;[Epub]     CrossRef
  • 4,521 View
  • 315 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
IBD
Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
Intest Res 2024;22(1):75-81.   Published online November 1, 2023
DOI: https://doi.org/10.5217/ir.2023.00065
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflammatory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity.
Methods
A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn’s disease) were included in this study. FCP and serum C-reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings.
Results
Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating characteristic curve showed that both FCP and IMA had diagnostic value in predicting non-mucosal healing. When the Ln(FCP)+IMA/10 value was calculated using both factors, the predictive value for non-mucosal healing increased; however, no significant difference was observed.
Conclusions
IMA could be a candidate serum biomarker for predicting endoscopic mucosal healing in IBD.

Citations

Citations to this article as recorded by  
  • A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease
    Hyoun Woo Kang
    Intestinal Research.2024; 22(1): 3.     CrossRef
  • 3,488 View
  • 251 Download
  • 1 Crossref
Close layer
Microbiota
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):148-160.   Published online June 14, 2022
DOI: https://doi.org/10.5217/ir.2021.00168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The fecal microbiota of Korean patients with inflammatory bowel disease (IBD) was investigated with respect to disease phenotypes and taxonomic biomarkers for diagnosis and prognosis of IBD.
Methods
Fecal samples from 70 ulcerative colitis (UC) patients, 39 Crohn’s disease (CD) patients, and 100 healthy control individuals (HC) were collected. The fecal samples were amplified via polymerase chain reaction and sequenced using Illumina MiSeq. The relationships between fecal bacteria and clinical phenotypes were analyzed using the EzBioCloud database and 16S microbiome pipeline.
Results
The alpha-diversity of fecal bacteria was significantly lower in UC and CD (P<0.05) compared to that in HC. Bacterial community compositions in UC and CD were significantly different from that of HC according to Bray-Curtis dissimilarities, and there was also a difference between community composition in UC and CD (P=0.01). In UC, alpha-diversity was further decreased when the disease was more severe and the extent of disease was greater, and community composition significantly differed depending on the extent of the disease. We identified 9 biomarkers of severity and 6 biomarkers of the extent of UC. We also identified 5 biomarkers of active disease and 3 biomarkers of ileocolonic involvement in CD. Lachnospiraceae and Ruminococcus gnavus were biomarkers for better prognosis in CD.
Conclusions
The fecal microbiota profiles of IBD patients were different from those of HC, and several bacterial taxa may be used as biomarkers to determine disease phenotypes and prognosis. These data may also help discover new therapeutic targets for IBD.

Citations

Citations to this article as recorded by  
  • Gut microbiota dysbiosis in a novel mouse model of colitis potentially increases the risk of colorectal cancer
    Abrory A. C. Pramana, Guanying Bianca Xu, Siyuan Liang, Erick Omar Garcia Vazquez, Jacob M. Allen, Brett R. Loman, Wenyan Mei, Yuan-Xiang Pan, Hong Chen
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2025; 328(6): G831.     CrossRef
  • Gut bacteriome in inflammatory bowel disease: An update on recent advances
    Aditya Bajaj, Manasvini Markandey, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2024; 43(1): 103.     CrossRef
  • An Update on the Role and Potential Molecules in Relation to Ruminococcus gnavus in Inflammatory Bowel Disease, Obesity and Diabetes Mellitus
    Jinni Hong, Tingting Fu, Weizhen Liu, Yu Du, Junmin Bu, Guojian Wei, Miao Yu, Yanshan Lin, Cunyun Min, Datao Lin
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1235.     CrossRef
  • Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
    Junyi Bai, Ying Wang, Fuhao Li, Yueyao Wu, Jun Chen, Meng Li, Xi Wang, Bin Lv
    Science Progress.2024;[Epub]     CrossRef
  • Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet’s Disease
    Yehyun Park, Jae Bum Ahn, Da Hye Kim, I Seul Park, Mijeong Son, Ji Hyung Kim, Hyun Woo Ma, Seung Won Kim, Jae Hee Cheon
    International Journal of Molecular Sciences.2024; 25(12): 6697.     CrossRef
  • Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
    Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
    Gut Pathogens.2024;[Epub]     CrossRef
  • Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
    Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
    Gut and Liver.2023; 17(1): 108.     CrossRef
  • Ruminococcus gnavus: friend or foe for human health
    Emmanuelle H Crost, Erika Coletto, Andrew Bell, Nathalie Juge
    FEMS Microbiology Reviews.2023;[Epub]     CrossRef
  • The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
    Dermatology and Therapy.2023; 13(7): 1465.     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kwang Woo Kim
    Gut and Liver.2023; 17(6): 954.     CrossRef
  • Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease
    Hyuk Yoon, Sunghyouk Park, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
    Microorganisms.2023; 11(12): 2882.     CrossRef
  • A Machine Learning-Based Diagnostic Model for Crohn’s Disease and Ulcerative Colitis Utilizing Fecal Microbiome Analysis
    Hyeonwoo Kim, Ji Eun Na, Sangsoo Kim, Tae-Oh Kim, Soo-Kyung Park, Chil-Woo Lee, Kyeong Ok Kim, Geom-Seog Seo, Min Suk Kim, Jae Myung Cha, Ja Seol Koo, Dong-Il Park
    Microorganisms.2023; 12(1): 36.     CrossRef
  • 5,816 View
  • 482 Download
  • 12 Web of Science
  • 13 Crossref
Close layer
Review
Novel biomarkers for the diagnosis and prognosis of colorectal cancer
Hyung-Hoon Oh, Young-Eun Joo
Intest Res 2020;18(2):168-183.   Published online November 30, 2019
DOI: https://doi.org/10.5217/ir.2019.00080
AbstractAbstract PDFPubReaderePub
Colorectal cancer (CRC) is among the most common malignancies and remains a major cause of cancer-related death worldwide. Despite recent advances in surgical and multimodal therapies, the overall survival of advanced CRC patients remains very low. Cancer progression, including invasion and metastasis, is a major cause of death among CRC patients. The underlying mechanisms of action resulting in cancer progression are beginning to unravel. The reported molecular and biochemical mechanisms that might contribute to the phenotypic changes in favor of carcinogenesis include apoptosis inhibition, enhanced tumor cell proliferation, increased invasiveness, cell adhesion perturbations, angiogenesis promotion, and immune surveillance inhibition. These events may contribute to the development and progression of cancer. A biomarker is a molecule that can be detected in tissue, blood, or stool samples to allow the identification of pathological conditions such as cancer. Thus, it would be beneficial to identify reliable and practical molecular biomarkers that aid in the diagnostic and therapeutic processes of CRC. Recent research has targeted the development of biomarkers that aid in the early diagnosis and prognostic stratification of CRC. Despite that, the identification of diagnostic, prognostic, and/or predictive biomarkers remains challenging, and previously identified biomarkers might be insufficient to be clinically applicable or offer high patient acceptability. Here, we discuss recent advances in the development of molecular biomarkers for their potential usefulness in early and less-invasive diagnosis, treatment, and follow-up of CRC.

Citations

Citations to this article as recorded by  
  • Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis
    Sungyeon Kim, Myunghee Kang, Soyeon Jeong, Jisup Kim, Kyoung Oh Kim, Won‐Suk Lee, Jeong‐Heum Baek, Jung Ho Kim, Seungyoon Nam
    Molecular Oncology.2025;[Epub]     CrossRef
  • Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab—20 Years of Therapeutic Success and Controversy
    Elena Chitoran, Vlad Rotaru, Daniela-Cristina Stefan, Giuseppe Gullo, Laurentiu Simion
    Cancers.2025; 17(7): 1126.     CrossRef
  • The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses
    Sandeep Samethadka Nayak, Daniyal Ameen, Sara Nobakht, Ranjan Nayak, Shrinidhi Vilas Prabhu, Mohammad-Hossein Keivanlou, Soheil Hassanipour, Ehsan Amini-Salehi, Nisarg Thakker
    Systematic Reviews.2025;[Epub]     CrossRef
  • Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy
    V. Kostiuchenko, I. Vynnychenko, Y. Moskalenko, V. Pohorila
    Regulatory Mechanisms in Biosystems.2025; 33(1): e25020.     CrossRef
  • ZNF746 plays cardinal roles on colorectal cancer (CRC) cell invasion and migration and regulates mitochondrial dynamics and morphological changes of CRC cells—Role of combined melatonin and 5‐FU regimen
    Chi‐Ruei Huang, Yu‐Ting Chu, Chia‐Lo Chang, Hon‐Kan Yip, Hong‐Hwa Chen
    Journal of Cellular Biochemistry.2024;[Epub]     CrossRef
  • Anti‐angiogenesis in colorectal cancer therapy
    Zhenni Yang, Xuqian Zhang, Xiaozhe Bai, Xiaonan Xi, Wentian Liu, Weilong Zhong
    Cancer Science.2024; 115(3): 734.     CrossRef
  • Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
    Shunkang Yan, Jiandong Zhang, Lianghe Li, Gang Chen, Zhongsheng Chen, Wei Zhan
    Cancer Biomarkers.2024; 40(1): 95.     CrossRef
  • Identification of Hub genes with prognostic values in colorectal cancer by integrated bioinformatics analysis
    Shan Li, Ting Li, Yan-Qing Shi, Bin-Jie Xu, Yu-Yong Deng, Xu-Guang Sun
    Cancer Biomarkers.2024; 40(1): 27.     CrossRef
  • Exploring the integration of nanotechnology in the development and application of biosensors for enhanced detection and monitoring of colorectal cancer
    Ashkan Hajjafari, Soheil Sadr, Abbas Rahdar, Mansour Bayat, Narges Lotfalizadeh, Shiva Dianaty, Arezou Rezaei, Soroush Partovi Moghaddam, Khashayar Hajjafari, Pouria Ahmadi Simab, Zelal Kharaba, Hassan Borji, Sadanand Pandey
    Inorganic Chemistry Communications.2024; 164: 112409.     CrossRef
  • The potential role of SNHG16/ miRNA-146a/ TRAF6 signaling pathway in the protective effect of zoledronate against colorectal cancer and associated osteoporosis in mouse model
    Amany Helmy Mohamed, Ahmed Noureldin Hassan, Nesma Hussein Abdel hay, Manar Fouad Ahmed, Marwa M. El Sawy, Mohamed M. Sonbol, Reham Hussein Mohamed
    International Immunopharmacology.2024; 133: 112125.     CrossRef
  • An Updated Review on Molecular Biomarkers in Diagnosis and Therapy of Colorectal Cancer
    Shruthi Nagainallur Ravichandran, Makalakshmi Murali Kumar, Alakesh Das, Antara Banerjee, Suhanya Veronica, Alexander Sun-Zhang, Hong Zhang, Muralidharan Anbalagan, Xiao-Feng Sun, Surajit Pathak
    Current Cancer Drug Targets.2024; 24(6): 595.     CrossRef
  • Investigating the biomarker value of circRNAs in the diagnosis of colorectal cancer: a systematic review
    Tahereh Latifi-Pakdehi, Ali Khezrian, Amin Doosti-Irani, Saeid Afshar, Ali Mahdavinezhad
    Discover Oncology.2024;[Epub]     CrossRef
  • The diagnostic value of serum Ephrin-A1 in patients with colorectal cancer
    Qi-Xin Su, Ze-Jun Zheng, Ying-Hua Xie, Ling-Yu Chu, Yi-Wei Lin, Yin-Qiao Liu, Xin-Xin Li, Yu-Hui Peng, Yi-Wei Xu, Jian-Jun Xie
    Scientific Reports.2024;[Epub]     CrossRef
  • Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer
    Danique J. I. Heuvelings, Anne G. W. E. Wintjens, Laura Moonen, Sanne M. E. Engelen, Ignace H. J. T. de Hingh, Liselot B. Valkenburg-van Iersel, Marcel den Dulk, Jan Beckervordersandforth, Sharon G. M. Thijssen, Daphne J. G. Leunissen, Laurents P. S. Stas
    International Journal of Molecular Sciences.2023; 24(16): 12830.     CrossRef
  • A guide to mass spectrometric analysis of extracellular vesicle proteins for biomarker discovery
    Iqbal Jalaludin, David M. Lubman, Jeongkwon Kim
    Mass Spectrometry Reviews.2023; 42(2): 844.     CrossRef
  • Comment on " Positive fecal immunochemical test results are associated with non-colorectal cancer mortality"
    Yong Eun Park
    The Korean Journal of Internal Medicine.2023; 38(2): 264.     CrossRef
  • Simple Isothermal and Label-Free Strategy for Colorectal Cancer Potential Biomarker miR-625-5p Detection
    Yifei Chen, Lizhen Ye, Hui Chen, Tingting Fan, Cheng Qiu, Yan Chen, Yuyang Jiang
    Biosensors.2023; 13(1): 78.     CrossRef
  • DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review
    Danique J. I. Heuvelings, Anne G. W. E. Wintjens, Julien Luyten, Guus E. W. A. Wilmink, Laura Moonen, Ernst-Jan M. Speel, Ignace H. J. T. de Hingh, Nicole D. Bouvy, Andrea Peeters
    Cancers.2023; 15(2): 549.     CrossRef
  • The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer
    Xiao Meng Pei, Heong Ting Wong, Simon Siu Man Ng, Wing Wa Leung, Yee Ni Wong, Hin Fung Tsang, Amanda Kit Ching Chan, Yin Kwan Evelyn Wong, Allen Chi Shing Yu, Aldrin Kay Yuen Yim, William Chi Shing Cho, John Kwok Cheung Chan, Kwong Fai Wong, John M Luk, W
    Expert Review of Molecular Diagnostics.2023; 23(2): 171.     CrossRef
  • lncRNA HCG11 Promotes Colorectal Cancer Cell Malignant Behaviors via Sponging miR-26b-5p
    Song Guo, Bingtan Song, Lin Li, Hesheng Li, Tao Yang, Lianmeng Cao, Jian Wang, Fu Wang
    Journal of Immunology Research.2023; 2023: 1.     CrossRef
  • Ferroptosis open a new door for colorectal cancer treatment
    Hong Liang, Xia He, Yitong Tong, Niuniu Bai, Yushu Pu, Ke Han, Yi Wang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
    Huafeng Jiang, Senjun Zhou, Gang Li
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer
    Devesh u kapoor, Rahul Garg, Mansi Gaur, Bhupendra G. Prajapati, Gyan Agrawal, Sankha Bhattacharya, Gehan M. Elossaily
    Results in Chemistry.2023; 6: 101167.     CrossRef
  • Expression of an oxysterol-metabolizing enzyme in colorectal cancer and its relation to tumor cell behavior and prognosis
    Ki-Hyun Kim, Young-Lan Park, Sun-Young Park, Young-Eun Joo
    Pathology - Research and Practice.2023; 251: 154875.     CrossRef
  • Recent Developments in Diagnostic and Prognostic Biomarkers for Colorectal Cancer: A Narrative Review
    Nefeli Giannopoulou, Constantina Constantinou
    Oncology.2023; 101(10): 675.     CrossRef
  • Diagnostic value of serum procalcitonin and C-reactive protein in discriminating between bacterial and nonbacterial colitis: a retrospective study
    Jae Yong Lee, So Yeon Lee, Yoo Jin Lee, Jin Wook Lee, Jeong Seok Kim, Ju Yup Lee, Byoung Kuk Jang, Woo Jin Chung, Kwang Bum Cho, Jae Seok Hwang
    Journal of Yeungnam Medical Science.2023; 40(4): 388.     CrossRef
  • IDENTIFICATION AND FUNCTIONAL ANALYSIS OF microRNA AS PROSPECTIVE PROGNOSTIC MARKERS OF COLORECTAL CANCER
    S.V. Maliborska, T.V. Zadvornyi
    Oncology.2023; 25(3): 207.     CrossRef
  • PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer
    Akira Koshino, Aya Nagano, Akinobu Ota, Toshinori Hyodo, Akane Ueki, Masayuki Komura, Akane Sugimura-Nagata, Masahide Ebi, Naotaka Ogasawara, Kenji Kasai, Yoshitaka Hosokawa, Kunio Kasugai, Satoru Takahashi, Shingo Inaguma
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Medicina de precisión: rol de la anatomía patológica en diagnóstico y tratamiento personalizado
    Tania S. Quiroz, Facundo Las Heras
    Revista Médica Clínica Las Condes.2022; 33(1): 36.     CrossRef
  • Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer
    Seung Wook Hong, Seohyun Lee, Yun Jae Kim, Soyeon Ahn, In Ja Park, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jaeil Kim, Sang‐Yeob Kim, Seung‐Jae Myung
    Journal of Gastroenterology and Hepatology.2022; 37(3): 542.     CrossRef
  • SPATA18 Expression Predicts Favorable Clinical Outcome in Colorectal Cancer
    Akane Sugimura-Nagata, Akira Koshino, Kazuhiro Nagao, Aya Nagano, Masayuki Komura, Akane Ueki, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kenji Kasai, Satoru Takahashi, Kunio Kasugai, Shingo Inaguma
    International Journal of Molecular Sciences.2022; 23(5): 2753.     CrossRef
  • Osteoporosis Is Associated with an Increased Risk of Colorectal Adenoma and High-Risk Adenoma: A Retrospective, Multicenter, Cross-Sectional, Case-Control Study
    Ji Hyung Nam, Myung Koh, Hyoun Woo Kang, Kum Hei Ryu, Dong Seok Lee, Su Hwan Kim, Dong Kee Jang, Ji Bong Jeong, Ji Won Kim, Kook Lae Lee, Dong Jun Oh, Yun Jeong Lim, Seong-Joon Koh, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2022; 16(2): 269.     CrossRef
  • The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer
    Kazuhiro Nagao, Akira Koshino, Akane Sugimura-Nagata, Aya Nagano, Masayuki Komura, Akane Ueki, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kenji Kasai, Satoru Takahashi, Kunio Kasugai, Shingo Inaguma
    International Journal of Molecular Sciences.2022; 23(6): 3252.     CrossRef
  • Risk of Metachronous Colorectal Advanced Neoplasia and Cancer in Patients With 3–4 Nonadvanced Adenomas at Index Colonoscopy: A Systematic Review and Meta-Analysis
    Suyeon Park, Seong Ran Jeon, Hyun Gun Kim, Yunho Jung, Min-Seob Kwak, Su Young Kim, Jong Wook Kim, Seung-Joo Nam, Eun Hye Oh, Seon-Young Park, Soo-Kyung Park, Jeong-Sik Byeon, Sun-Jin Boo, Dong Hoon Baek, Soon Man Yoon, Jaeyoung Chun, Jooyoung Lee, Miyoun
    American Journal of Gastroenterology.2022; 117(4): 588.     CrossRef
  • MicroRNA Expression Profiling Predicts Nodal Status and Disease Recurrence in Patients Treated with Curative Intent for Colorectal Cancer
    Matthew G. Davey, Gerard Feeney, Heidi Annuk, Maxwell Paganga, Emma Holian, Aoife J. Lowery, Michael J. Kerin, Nicola Miller
    Cancers.2022; 14(9): 2109.     CrossRef
  • Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer
    Joyeon Kang, Doyeon Lee, Kyoung Jin Lee, Jaepil Eric Yoon, Ji-Hee Kwon, Yoojeong Seo, Janghyun Kim, Shin Young Chang, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Cancers.2022; 14(12): 2881.     CrossRef
  • The Role of Long Non-Coding RNAs in Epithelial-Mesenchymal Transition-Related Signaling Pathways in Prostate Cancer
    Dexin Shen, Hongwei Peng, Caixia Xia, Zhao Deng, Xi Tong, Gang Wang, Kaiyu Qian
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer
    Cristiana Caliceti, Angela Punzo, Alessia Silla, Patrizia Simoni, Giulia Roda, Silvana Hrelia
    Nutrients.2022; 14(14): 2964.     CrossRef
  • An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer
    Pouria Samadi, Meysam Soleimani, Fatemeh Nouri, Fatemeh Rahbarizadeh, Rezvan Najafi, Akram Jalali
    BMC Cancer.2022;[Epub]     CrossRef
  • Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer
    Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS
    Qing Chen, Lin Zhou, De Ma, Juan Hou, Yuxin Lin, Jie Wu, Min Tao
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • Associations of C‑X‑C motif chemokine ligands 1/2/8/13/14 with clinicopathological features and survival profile in patients with colorectal cancer
    Xiaofan Luo, Jiandong Tai, Yuhang Zhao, Pingwei Zhao, Di Sun, Lei Wang
    Oncology Letters.2022;[Epub]     CrossRef
  • Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
    Ji Young Chang
    Clinical Endoscopy.2022; 55(5): 699.     CrossRef
  • Clinical applications and optimization of patient-derived organoids in intestinal diseases
    Tae Il Kim
    Organoid.2022; 2: e22.     CrossRef
  • Novel laboratory biomarkers in colorectal cancer management
    Marija Gegovska, Marija Hiljadnikova-Bajro
    Macedonian Pharmaceutical Bulletin.2022; 68(03): 333.     CrossRef
  • Higher ETV5 Expression Associates With Poor 5-Florouracil-Based Adjuvant Therapy Response in Colon Cancer
    Anil K. Giri
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Cell-to-Cell Communication by Host-Released Extracellular Vesicles in the Gut: Implications in Health and Disease
    Natalia Diaz-Garrido, Cecilia Cordero, Yenifer Olivo-Martinez, Josefa Badia, Laura Baldomà
    International Journal of Molecular Sciences.2021; 22(4): 2213.     CrossRef
  • High phospho‐histone H3 expression uniquely predicts favorable survival among four markers of cellular proliferation in colorectal cancer
    Akira Koshino, Satoshi Inoue, Akane Sugimura‐Nagata, Takeshi Nishiyama, Hideki Murakami, Hideaki Ito, Miho Riku, Akihito Inoko, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kunio Kasugai, Kenji Kasai, Shingo Inaguma
    Pathology International.2021; 71(5): 316.     CrossRef
  • Editorial Comment on High phospho‐histone H3 expression uniquely predicts favorable survival among four markers of cellular proliferation in colorectal cancer
    Hiroshi Kijima
    Pathology International.2021; 71(5): 325.     CrossRef
  • Correlation of CD47 Expression with Adverse Clinicopathologic Features and an Unfavorable Prognosis in Colorectal Adenocarcinoma
    Hyunsung Kim, Seungyun Jee, Yeseul Kim, Jongmin Sim, Seongsik Bang, Hwang Kyu Son, Hosub Park, Jaekyung Myung, Young Hyeh Ko, Seung Sam Paik
    Diagnostics.2021; 11(4): 668.     CrossRef
  • A Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer
    Young-Lan Park, Sun-Young Park, Hyung-Hoon Oh, Min-Woo Chung, Ji-Yun Hong, Ki-Hyun Kim, Dae-Seong Myung, Sung-Bum Cho, Wan-Sik Lee, Hyun-Soo Kim, Young-Eun Joo
    Cancers.2021; 13(8): 1927.     CrossRef
  • Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
    Samantha Epistolio, Marco Cefalì, Paolo Spina, Francesca Molinari, Alessandra Movilia, Massimiliano Cergnul, Luca Mazzucchelli, Sara De Dosso, Milo Frattini, Piercarlo Saletti
    Oncotarget.2021; 12(11): 1046.     CrossRef
  • Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
    Yoonsuk Jung, Eui Im, Jinhee Lee, Hyeah Lee, Changmo Moon
    Journal of Personalized Medicine.2021; 11(6): 497.     CrossRef
  • Multi-omics analyses of human colorectal cancer revealed three mitochondrial genes potentially associated with poor outcomes of patients
    Wei Zhang, Liewen Lin, Ligang Xia, Wanxia Cai, Weier Dai, Chang Zou, Lianghong Yin, Donge Tang, Yong Xu, Yong Dai
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • High expression of DNA damage-inducible transcript 4 (DDIT4) is associated with advanced pathological features in the patients with colorectal cancer
    Fahimeh Fattahi, Leili Saeednejad Zanjani, Zohreh Habibi Shams, Jafar Kiani, Mitra Mehrazma, Mohammad Najafi, Zahra Madjd
    Scientific Reports.2021;[Epub]     CrossRef
  • Predictors of clinical outcomes of self-expandable metal stent treatment for malignant colorectal obstruction
    Bora Han, Ji-Yun Hong, Eun Myung, Hyung-Hoon Oh, Hee-Chan Yang, Sang-Wook Kim, Jun Lee, Seong-Jung Kim, Yeom-Dong Han, Geom-Seok Seo, Gun-Young Hong, Ho-Dong Kim, Hyun-Soo Kim, Young-Eun Joo
    Medicine.2021; 100(27): e26616.     CrossRef
  • Risk-stratified colorectal cancer screening for optimal use of colonoscopy resources
    Dong-Hoon Yang
    The Korean Journal of Internal Medicine.2021; 36(4): 839.     CrossRef
  • LncRNA AFAP1-AS1 Promotes the Progression of Colorectal Cancer through miR-195-5p and WISP1
    Yongsheng Li, Zhongpeng Zhu, Xiaokun Hou, Yongjun Sun, Muhammad Wasim Khan
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • RNA-sequencing identification and validation of genes differentially expressed in high-risk adenoma, advanced colorectal cancer, and normal controls
    Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Seung Bin Park, Hee Sook Yoon, Sang Hee Kang, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim, Han-Kyeom Kim
    Functional & Integrative Genomics.2021; 21(3-4): 513.     CrossRef
  • Overview of serum and tissue markers in colorectal cancer: a primer for radiologists
    Apurva Bonde, Daniel A. Smith, Elias Kikano, Jennifer M. Yoest, Sree H. Tirumani, Nikhil H. Ramaiya
    Abdominal Radiology.2021; 46(12): 5521.     CrossRef
  • Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC
    Huisheng Liu, JiaYuan Zhong, JiaQi Hu, ChongYin Han, Rui Li, XueQing Yao, ShiPing Liu, Pei Chen, Rui Liu, Fei Ling
    Molecular Therapy - Oncolytics.2021; 22: 495.     CrossRef
  • Faecal Diagnostic Biomarkers for Colorectal Cancer
    Andrea Cruz, Carla M. Carvalho, Alexandra Cunha, Anais Crespo, Águeda Iglesias, Laura García-Nimo, Paulo P. Freitas, Joaquín Cubiella
    Cancers.2021; 13(21): 5568.     CrossRef
  • Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis
    Tao Wang, Jiandong Fei, Shuangfa Nie, Ajay Goel
    PLOS ONE.2021; 16(11): e0260035.     CrossRef
  • Detection of Microsatellite Instability in Colorectal Cancer Patients With a Plasma-Based Real-Time PCR Analysis
    Namjoo Kim, Sung Min Kim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Sang Hee Kang, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Identification of Whole-Serum Glycobiomarkers for Colorectal Carcinoma Using Reverse-Phase Lectin Microarray
    Tomas Bertok, Aniko Bertokova, Eduard Jane, Michal Hires, Juvissan Aguedo, Maria Potocarova, Ludovit Lukac, Alica Vikartovska, Peter Kasak, Lubor Borsig, Jan Tkac
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • LncRNA PTTG3P Sponge Absorbs microRNA-155-5P to Promote Metastasis of Colorectal Cancer


    Ning Liu, Lei Dou, Xinxin Zhang
    OncoTargets and Therapy.2020; Volume 13: 5283.     CrossRef
  • 16,130 View
  • 717 Download
  • 80 Web of Science
  • 66 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP